Real-World data to show if HAE drug works in kids
NCT ID NCT07251933
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study tracks 40 children aged 2 to 12 with hereditary angioedema (HAE) who are taking lanadelumab to prevent sudden, painful swelling attacks. Researchers will look at medical records to see how long kids stay attack-free and how the drug performs in daily life. No new treatments are given; the goal is to understand real-world effectiveness and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lanadelumab (Takhzyro)
- What this could lead to
- If successful, this study could confirm that lanadelumab effectively prevents swelling attacks in children with HAE in everyday settings.
- What could go wrong
- This is an observational study using existing records, not a controlled trial, so results may be less reliable. It is also small (40 children) and focused on a rare condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HM- Hopital de La Timone
Marseille, Bouches-du-Rhone, 13005, France
-
AP-HP - Hopital Armand Trousseau
Paris, 75012, France
-
CHU de Grenoble Alpes - Hopital Couple-Enfant
La Tronche, Grenoble, 38700, France
-
Centro de Alergia e Inmunologia Clinica Mar del Plata
Mar del Plata, Buenos Aires, 7600, Argentina
-
Charite Campus Virchow-Klinikum-Augustenburger Platz 1
Berlin, 13353, Germany
-
Children and Youth Health Care Institute of Vojvodina
Novi Sad, 21000, Serbia
-
Childrens University Hospital
Belgrade, 11000, Serbia
-
Hadassah Medical Center- Ein Kerem - PPDS
Jerusalem, 9112001, Israel
-
Hamophilie Zentrum Rhein Main GmbH
Frankfurt am Main, Hesse, 60596, Germany
-
Hospital Italiano de Buenos Aires
Buenos Aires, Ciudad Autonoma de BuenosAires, C1199ABB, Argentina
-
Hospital de Ninos Sor Maria Ludovica
La Plata, Buenos Aires, B1904CSI, Argentina
-
Hospital de Pediatria S.A.M.I.C.- Prof. Dr. Juan P. Garrahan
Ciudad de Buenos Aires, Buenos Aires F.D., C1249ABN, Argentina
-
Klinikum St. Georg Leipzig
Leipzig, Saxony, 4129, Germany
-
Mother and Child Health Care Institute of Serbia Dr Vukan Cupic
Belgrade, 11000, Serbia
-
Royal Victoria Infirmary
Newcastle upon Tyne, Tyne and Wear, NE1 4LP, United Kingdom
-
Sanatorio de la Canada-Cordoba
Córdoba, X5000BSQ, Argentina
-
Schneider Childrens Medical Center of Israel Petah Tikvah PIN
Petah Tikva, 4910000, Israel
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
-
The Royal London Hospital - PPDS
London, E1 1FR, United Kingdom
-
Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
Lübeck, Schleswig-Holstein, 23538, Germany
-
Universitatsklinikum Frankfurt am Main
Frankfurt am Main, Hesse, 60590, Germany
-
Universitatsklinikum Leipzig
Leipzig, Saxony, 4103, Germany
-
Universitatsklinikum Munster
Münster, North Rhine-Westphalia, 48149, Germany
-
Universitatsklinikum Ulm
Ulm, Baden-Wurttemberg, 89081, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists hunt for blood clues to tame unpredictable swelling attacks
- HAE patients and caregivers speak out: the hidden costs of On-Demand treatment
- Real-world study shows lanadelumab keeps HAE attacks at bay for many patients
- Takhzyro under the microscope: Real-World safety check for rare swelling disease
- New hope for HAE patients: experimental drug aims to slash attack rate
- New RNA drug shows promise in preventing HAE attacks in ongoing study